Tags

Type your tag names separated by a space and hit enter

Cannabinoids for the treatment of inflammation.
Curr Opin Investig Drugs. 2007 May; 8(5):373-84.CO

Abstract

Cannabinoids are effective at suppressing immune and inflammation functions in leukocytes in vitro, and in animal models of acute inflammation, such as the mouse hind paw, ear and air pouch models, as well as gastrointestinal, pulmonary, myocardial, vascular, periodontal, neural, hepatic, pancreatic and arthritic inflammation models. The non-psychoactive cannabinoid receptor CB2 is emerging as a critical target for cannabinoid regulation of inflammation, and thus CB2-selective agonists are undergoing intense investigation and research. This review discusses the evidence for cannabinoid regulation of inflammation across a range of models and highlights the most promising drug candidates.

Authors+Show Affiliations

University of Otago, Department of Pharmacology and Toxicology, P.O. Box 913, Dunedin, New Zealand. john.ashton@stonebow.otago.ac.nz

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17520866

Citation

Ashton, John C.. "Cannabinoids for the Treatment of Inflammation." Current Opinion in Investigational Drugs (London, England : 2000), vol. 8, no. 5, 2007, pp. 373-84.
Ashton JC. Cannabinoids for the treatment of inflammation. Curr Opin Investig Drugs. 2007;8(5):373-84.
Ashton, J. C. (2007). Cannabinoids for the treatment of inflammation. Current Opinion in Investigational Drugs (London, England : 2000), 8(5), 373-84.
Ashton JC. Cannabinoids for the Treatment of Inflammation. Curr Opin Investig Drugs. 2007;8(5):373-84. PubMed PMID: 17520866.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabinoids for the treatment of inflammation. A1 - Ashton,John C, PY - 2007/5/25/pubmed PY - 2007/6/23/medline PY - 2007/5/25/entrez SP - 373 EP - 84 JF - Current opinion in investigational drugs (London, England : 2000) JO - Curr Opin Investig Drugs VL - 8 IS - 5 N2 - Cannabinoids are effective at suppressing immune and inflammation functions in leukocytes in vitro, and in animal models of acute inflammation, such as the mouse hind paw, ear and air pouch models, as well as gastrointestinal, pulmonary, myocardial, vascular, periodontal, neural, hepatic, pancreatic and arthritic inflammation models. The non-psychoactive cannabinoid receptor CB2 is emerging as a critical target for cannabinoid regulation of inflammation, and thus CB2-selective agonists are undergoing intense investigation and research. This review discusses the evidence for cannabinoid regulation of inflammation across a range of models and highlights the most promising drug candidates. SN - 1472-4472 UR - https://www.unboundmedicine.com/medline/citation/17520866/Cannabinoids_for_the_treatment_of_inflammation_ L2 - https://www.lens.org/lens/search/patent/list?q=citation_id:17520866 DB - PRIME DP - Unbound Medicine ER -